Gina Kolata is a reporter at the New York Times. She focuses on medicine and healthcare, exploring topics such as drug development, gene therapy, and the impact of treatments on patients. Gina's work has been featured in numerous publications, including Yahoo News, The Philadelphia Inquirer, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Gina Kolata's coverage focuses on medical advancements, gene editing, sickle cell disease, cancer treatment, and weight loss drugs. She frequently cites data in her articles, indicating a reliance on evidence-based reporting.
To effectively reach out to Gina Kolata, consider providing insights based on clinical trial results or scientific studies related to the topics she covers. Experts who can provide detailed analysis of the efficacy and safety profiles of new medical treatments or breakthroughs may be particularly valuable for her reporting.
As an experienced health journalist with a national focus in the United States, she is likely receptive to pitches related to innovative healthcare technologies or groundbreaking research from reputable sources within the field.
This information evolves through artificial intelligence and human feedback. Improve this profile .
National By Gina Kolata NYT News Service/Syndicate Stories July 31, 2026 3:15 PM
Nancy Wexler led the research to identify the gene responsible for Huntington's disease
By: Gina Kolata
The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
By: Gina Kolata
The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.
By: Gina Kolata
Novo Nordisk stunned the cardiology world recently when it announced that a large study it was running on an experimental drug for heart disease had failed.
Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.
About 400 million people worldwide have a rare disease, many of them children. A new centre hopes to improve their lives
By: Gina Kolata, Rebecca Robbins, Carolyn Y. Johnson
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.
